Immutep Ltd (AU:IMM) has released an update.
Immutep Limited has announced promising initial safety data from its first-in-human Phase I trial of IMP761, the world’s first LAG-3 agonist antibody. With no treatment-related adverse events reported so far, the study marks a significant step in potentially addressing the root cause of autoimmune diseases by restoring immune balance. Investors are keenly watching this development as the trial progresses with more data expected in 2025.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.